by In2Pharma | Aug 10, 2021 | News
Europe Marketing authorisation holders should review their manufacturing processes for all products containing chemically synthesised or biological active substances to identify and, if necessary, mitigate the risk of presence of nitrosamine...
by In2Pharma | Jul 26, 2021 | News
Belgium The FAMHP has developed a new online form for reporting suspected adverse events of treatments in animals. In this way the safety profile of the medicines can be improved. At www.eenbijwerkingmelden-dieren.be or...
